Passa al contenuto
Merck

SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans.

Cell (2022-01-14)
Philip A Mudd, Anastasia A Minervina, Mikhail V Pogorelyy, Jackson S Turner, Wooseob Kim, Elizaveta Kalaidina, Jan Petersen, Aaron J Schmitz, Tingting Lei, Alem Haile, Allison M Kirk, Robert C Mettelman, Jeremy Chase Crawford, Thi H O Nguyen, Louise C Rowntree, Elisa Rosati, Katherine A Richards, Andrea J Sant, Michael K Klebert, Teresa Suessen, William D Middleton, Joshua Wolf, Sharlene A Teefey, Jane A O'Halloran, Rachel M Presti, Katherine Kedzierska, Jamie Rossjohn, Paul G Thomas, Ali H Ellebedy
ABSTRACT

SARS-CoV-2 mRNA vaccines induce robust anti-spike (S) antibody and CD4+ T cell responses. It is not yet clear whether vaccine-induced follicular helper CD4+ T (TFH) cell responses contribute to this outstanding immunogenicity. Using fine-needle aspiration of draining axillary lymph nodes from individuals who received the BNT162b2 mRNA vaccine, we evaluated the T cell receptor sequences and phenotype of lymph node TFH. Mining of the responding TFH T cell receptor repertoire revealed a strikingly immunodominant HLA-DPB1∗04-restricted response to S167-180 in individuals with this allele, which is among the most common HLA alleles in humans. Paired blood and lymph node specimens show that while circulating S-specific TFH cells peak one week after the second immunization, S-specific TFH persist at nearly constant frequencies for at least six months. Collectively, our results underscore the key role that robust TFH cell responses play in establishing long-term immunity by this efficacious human vaccine.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Mouse Anti-Human IgA Antibody, clone M24A, heavy chain, FITC conjugated, clone M24A, Chemicon®, from mouse